Lifeward Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined year-over-year due to AlterG shipment delays, but ReWalk sales grew 11% and international expansion continued. Liquidity improved with new financing and the Oratech acquisition, while operational efficiency gains offset lower revenue.
Fiscal Year 2025
-
FY 2025 revenue fell ~14%, while losses and operating cash use narrowed; ReWalk unit sales rose 22%. The Oramed transaction and Skelable acquisition expand funding and the product pipeline, while reimbursement and commercial execution remain key priorities.
-
Q3 2025 saw record ReWalk placements, 8% sequential revenue growth, and improved margins, driven by Medicare sales and operational efficiencies. Liquidity was enhanced with a $3M loan, and full-year guidance was reaffirmed, with strong pipelines in the U.S. and Europe.
-
Q2 2025 revenue was $5.7M, down 15% year-over-year but up 14% sequentially, with record ReWalk Medicare placements and operational improvements. Guidance for 2025 was reset to $24–$26M revenue and a $12–$14M non-GAAP net loss, with gradual growth expected.
-
Key milestones in technology, reimbursement, and operational efficiency position the company for growth and profitability by 2026. Integrated product lines address both clinic and home markets, with expanding coverage and a unified infrastructure supporting financial and market access goals.
-
Q1 2025 revenue reached $5.0M, with underlying growth after adjusting for prior year catch-up revenue. Gross margin improved to 42.2%, and cost reductions lowered operating loss. Full-year guidance of $28–$30M in sales and a Q4 adjusted operating loss of ~$1M were reaffirmed.
Fiscal Year 2024
-
Record 2024 revenue grew 85% YoY to $25.7M, with Q4 at $7.5M. 2025 guidance targets $28–$30M revenue, improved margins, and a Q4 operating loss at or below $1M. Strategic partnerships and expanded distribution are expected to drive growth and efficiency.
-
Q3 2024 revenue grew 39% year-over-year, driven by expanded Medicare coverage and strong ReWalk and AlterG pipelines. Operational efficiencies and cost reductions improved margins and cash burn, with full-year revenue guidance set at $25–26 million. Sequential growth and profitability depend on continued market expansion and CMS uptake.
-
Q2 2024 saw revenue surge 402% year-over-year to $6.7 million, driven by record ReWalk placements and strong Medicare payment flows. Gross margin and operating loss improved, with full-year revenue guidance reaffirmed at $28–32 million and break-even targeted by 2026.